Modified MMAF

Modified MMAF, an ADC cytotoxin, can be used in the synthesis of Antibody-drug Conjugate (ADC) . Modified MMAF can be used for the targeted research of cancer[1].

Product Specifications

CAS Number

1352202-47-1

UNSPSC

12352005

Target

Microtubule/Tubulin

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Cytoskeleton

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/modified-mmaf.html

Solubility

10 mM in DMSO

Smiles

O=C(N1CCCCO1)[C@@H](NC([C@H](C)[C@H]([C@@]2([H])N(CCC2)C(C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C([C@H](C(C)C)NC([C@@H](NC)C(C)C)=O)=O)=O)OC)=O)CC3=CNC4=CC=CC=C34

Molecular Formula

C45H73N7O8

Molecular Weight

840.10

References & Citations

[1]Polson AG, et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection [published correction appears in Cancer Res. 2010 Feb 1;70 (3) :1275. Slaga, Dion S [added]]. Cancer Res. 2009;69 (6) :2358-2364.|[2]Doronina SO, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006;17 (1) :114-124.